Lawmakers Demand Information On Vytorin Trials

Law360, New York (February 19, 2009, 12:00 AM EST) -- Merck & Co. Inc. and Schering-Plough Corp. returned to the hot seat Thursday, as lawmakers investigating the safety of Vytorin demanded more information about the controversial cholesterol drug’s clinical trials.

Chairman of the U.S. House of Representatives Energy and Commerce Committee Rep. Henry Waxman, D-Calif., and head of the subcommittee on oversight and investigations Rep. Bart Stupak, D-Mich., sent a letter to the pharmaceutical companies seeking more information about the monitoring boards responsible for overseeing patient safety in Vytorin trials last year.

Aiming to clarify the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.